Close Menu

NEW YORK – Gene editing company Inscripta announced on Tuesday that it has raised $125 million in a Series D financing round.

Paladin Capital Group led the round, with support from existing investors and new investors JS Capital Management and Oak HC/FT. The company said it has now raised $259.5 million — its Series C round raised a total of $105.5 million after two expansions.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Los Angeles Times reports that experts say Moderna's investigational COVID-19 vaccine results seem to be a step in the right direction, but that more testing is needed.

The Washington Post reports a new coronavirus data reporting protocol goes around the Centers for Disease Control and Prevention.

The Trump Administration has reversed its policy that could have stripped international students of their visas, the New York Times says.

In Cell this week: proteomic and metabolomic analysis of blood from COVID-19 patients, change in phosphorylation with infection, and more.